Scientific Protein Laboratories, LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Sep 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 2 to 23, 2026 · next Dec 2
- 1 fee due Sep 22, 2027The maintenance fee for Rp-Hplc Method for the Analysis and Quantification of Pancreatin Active Pharmaceutical Agents (US 9,291,630) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
- 1 fee due Oct 9, 2027The maintenance fee for Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin (US 11,952,603) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,291,630 | Rp-Hplc Method for the Analysis and Quantification of Pancreatin Active Pharmaceutical Agents In force · High confidence | In force | High confidence | |
| US 9,063,034 | Determination of the Absence or Presence of Bacillus Cereus Enterotoxin via a Western Blot In force · High confidence | In force | High confidence | |
| US 9,046,524 | Method to Quantify and Measure Excess Colipase in a Pancreatin Active Pharmaceutical Ingredient In force · High confidence | In force | High confidence | |
| US 9,677,114 | Method for Evaluating Degradation Pathways for Pancreatin Active Pharmaceutical Agents In force · High confidence | In force | High confidence | |
| US 10,093,916 | Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin In force · USPTO record | In force | USPTO record | |
| US 11,952,603 | Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 6: 1 lapsed for an unpaid fee · 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
Every application published under this name has become a patent.